- Home
- UFCS vs IOVA Comparison
UFCS vs IOVA Comparison
Compare UFCS & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFCS
- IOVA
- Stock Information
- Founded
- UFCS 1946
- IOVA 2007
- Country
- UFCS United States
- IOVA United States
- Employees
- UFCS N/A
- IOVA N/A
- Industry
- UFCS Property-Casualty Insurers
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UFCS Finance
- IOVA Health Care
- Exchange
- UFCS Nasdaq
- IOVA Nasdaq
- Market Cap
- UFCS 666.1M
- IOVA 597.7M
- IPO Year
- UFCS N/A
- IOVA N/A
- Fundamental
- Price
- UFCS $28.45
- IOVA $1.75
- Analyst Decision
- UFCS Buy
- IOVA Buy
- Analyst Count
- UFCS 2
- IOVA 10
- Target Price
- UFCS $30.00
- IOVA $12.22
- AVG Volume (30 Days)
- UFCS 88.8K
- IOVA 19.7M
- Earning Date
- UFCS 05-06-2025
- IOVA 05-08-2025
- Dividend Yield
- UFCS 2.25%
- IOVA N/A
- EPS Growth
- UFCS N/A
- IOVA N/A
- EPS
- UFCS 2.54
- IOVA N/A
- Revenue
- UFCS $1,288,423,000.00
- IOVA $212,679,000.00
- Revenue This Year
- UFCS $11.31
- IOVA $83.64
- Revenue Next Year
- UFCS $10.61
- IOVA $70.34
- P/E Ratio
- UFCS $11.20
- IOVA N/A
- Revenue Growth
- UFCS 14.59
- IOVA 11070.12
- 52 Week Low
- UFCS $18.04
- IOVA $1.64
- 52 Week High
- UFCS $31.70
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- UFCS 53.67
- IOVA 33.50
- Support Level
- UFCS $27.98
- IOVA $1.70
- Resistance Level
- UFCS $28.71
- IOVA $1.87
- Average True Range (ATR)
- UFCS 0.84
- IOVA 0.15
- MACD
- UFCS 0.03
- IOVA 0.02
- Stochastic Oscillator
- UFCS 76.02
- IOVA 27.50
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.